Furthermore, glioma patients with upregulated intratumoral IDO1 expression have shorter OS when compared to those with intermediate and downregulated IDO expression (44.3 vs. 34 vs. 24.9 months) [95]. The gene discussed is IDO1; the disease is central nervous system cancer.